(Q45782977)

English

A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24718809

0 references

A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer (English)

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24718809

0 references

immunohistochemistry

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Fatemeh Bahreini

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24718809%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Ali Reza Soltanian

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24718809%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Parvin Mehdipour

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24718809%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

10 April 2014

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/24718809

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24718809%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24718809%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

615-625

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24718809%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24718809%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

https://scigraph.springernature.com/pub.10.1007/s12282-014-0528-0

0 references

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

HER2 signatures in breast cancer: ready to go to print?

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Validation of tissue microarray biomarker expression of breast carcinomas in Saudi women

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens?

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Testing for HER2 in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Justification of the change from 10% to 30% for the immunohistochemical HER2 Scoring criterion in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and Unite

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Emerging technologies for assessing HER2 amplification

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Current use of HER2 tests.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

HER2--a discussion of testing approaches in the USA.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Assessment of HER2 status in breast cancer: why, when and how?

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Immunohistochemical Antibodies in Breast Cancer HER2 Diagnostics

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Re: A New Rabbit Monoclonal Antibody (4B5) for the Immunohistochemical (IHC) Determination of the HER2 Status in Breast Cancer: Comparison With CB11, Fluorescence In Situ Hybridization (FISH), and Interlaboratory Reproducibility

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Tissue microarray technology in breast cancer HER2 diagnostics

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

High Concordance Between Two Companion Diagnostics Tests

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-014-0528-0

21 January 2018

Identifiers

10.1007/S12282-014-0528-0

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24718809%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24718809%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45782977&oldid=2082349205"